Iorns: All marketed drugs require commercial industry to reach patients
Elizabeth Iorns · Elizabeth Iorns on Biotech Companies in YC · Y Combinator · Sep 13, 2017 · at 13:21
Elizabeth Iorns, cancer biologist and CEO of Science Exchange, explains why academic researchers must spin out discoveries into commercial biotech companies to bring therapies to market.
0:00 / 0:23exact quote · 24.0s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Because the reality is, you know, all innovations that come to market are through industry. So, you know, you don't see drugs on the market that came from academia. They were all, many of them discovered in the earliest phases, the basic research was done in academia, but then those were spun out into commercial biotech companies or pharmaceutical companies, licensed them, and took them through to commercialization.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Elizabeth Iorns
Iorns: Replication studies show most published scientific results are not reproducible
“So the reality is that the results that have been generated show that most published results are not reproducible.”
Iorns: Biotech Startups Do Not Need Business Co-Founders
“People have this Kind of illusion that they're, like, antisocial or, like, they don't understand business, and I just, like, completely disagree with that. I think scientists have to be very articulate. They frequently present in front of large audiences. They…”
Iorns: Backing Only Repeat Founders Excludes Academic Scientists with Domain Knowledge
“If you just fund like the same people over and over again, Then yes, they'll be like really efficient. They'll understand what it takes to do this, but you'll also miss out on all of the other innovative, different thinkers who are out there who actually made …”
Iorns: Scientific experiments often have 10x price differences for equivalent results
“So for example I was seeing literally 10 times price differences for an equivalent experiment because people really just didn't have access to what should it actually cost. And we see that still on Science Exchange today is that when people go and look for mul…”
Iorns: Biotech spinouts rely too much on figurehead principal investigators for funding
“I think that's still very difficult for scientists, particularly PhD and postdoc scientists, so they actually make the discoveries in these labs, so they're the ones doing the work but a lot of the time for them to actually be the ones to be the founder of the…”
Iorns: Scientific founders should not prioritize finding a business co-founder
“No, I don't think that should be a goal. I think I actually do have a business co-founder, so you would probably be mad that I say that, but, and he's great, and I literally couldn't have built Science Exchange without him, but not because of his business back…”